Ponesimod Shows Sustained Efficacy and Safety in RMS Over 5 Years
Could Ponesimod Change the Game for Multiple Sclerosis Patients?
In a 5-year extension of the OPTIMUM study, ponesimod 20 mg maintained a lower ARR (0.143) compared to teriflunomide switchers (0.184).
After five years, nearly half of people taking ponesimod for multiple sclerosis had no relapses, offering more stable lives with fewer unexp…
rTMS and TBS Improve Unilateral Spatial Neglect Post-Stroke: Meta-Analysis of 425 Patients
Can Brain Stimulation Help Stroke Survivors Overcome Neglect?
Meta-analysis of 17 studies (n=425) shows rTMS and TBS significantly reduce neglect severity in USN post-stroke, with rTMS improving LBT (SM…
Noninvasive brain stimulation like rTMS and TBS helped stroke survivors with spatial neglect regain attention and daily skills in a review o…
Psoriasis Linked to 24% Increased Stroke Risk, Especially in Severe Cases
Does Having Psoriasis Put You at Greater Risk for a Stroke?
Meta-analysis of 18 studies shows psoriasis patients have a 24% higher stroke risk (HR 1.24, 95% CI: 1.15-1.35, P<.05), with severe cases at…
People with severe psoriasis face a 36% higher risk of stroke, while even mild cases show a 9% increase in risk compared to those without th…